NXI Therapeutics is developing selective immunosuppressive drugs that target the coronin 1 protein to modulate T cell responses, thereby minimizing the risk of infections and tumors associated with conventional immunosuppressants. This approach aims to enhance the efficacy and safety of treatments for autoimmune diseases and organ transplantation without compromising the immune system's protective functions.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KFounders
Product
Problem
Conventional immunosuppressant drugs lack selectivity, increasing the risk of infections and tumors due to their broad impact on the immune system. This non-selective suppression affects all immune cells, compromising the body's ability to defend against pathogens and cancers.
Solution
NXI Therapeutics is developing a new generation of selective immunosuppressive drugs that target the coronin 1 protein to modulate T cell responses. By focusing on coronin 1, these drugs aim to selectively suppress the T cell immune responses responsible for graft rejection and autoimmunity, while preserving the protective immune responses needed to fight infections, respond to vaccinations, and prevent cancer. This targeted approach seeks to enhance the efficacy and safety of immunosuppressive therapy for autoimmune diseases and organ transplantation, avoiding the adverse effects associated with conventional, non-selective immunosuppressants.
Target Audience
The primary target audience includes individuals with autoimmune diseases and those undergoing organ transplantation who require immunosuppressive therapy.
Features
- Selective targeting of the coronin 1 protein in T cells
- Modulation of T cell responses to suppress autoimmunity and graft rejection
- Preservation of immune responses against infections, vaccination, and cancers